Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.37 USD | +1.46% |
|
+0.23% | -9.26% |
23/05 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
23/05 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.26% | 1.43B | |
+17.38% | 79.84B | |
+11.81% | 9.12B | |
+42.52% | 4.46B | |
-22.31% | 4.42B | |
+10.76% | 4.13B | |
+6.84% | 2.18B | |
-27.16% | 2.17B | |
+11.24% | 2.01B | |
-43.24% | 1.77B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study